hrp0098fc14.2 | Fetal and Neonatal Endocrinology | ESPE2024

Cord glucose: A normal reference and a potential of an ideal universal screening tool for pathological hyperinsulinism.

Siersbaek Julie , Soegaard Hansen Rasmus , Nybo Mads , thybo Christesen henrik

Background: Normal neonates exhibit a transitional state of physiological hyperinsulinism (HI) during the first 2-3 days of life as an adaption from the fetal state. Prolonged, pathological HI can cause irreversible cerebral damage, if not avoided by early diagnosis and prompt treatment. We hypothesized that umbilical cord blood glucose, included in routine cord gas analysis, can be used as an ideal screening tool for pathological HI. We first aimed to establi...

hrp0092p2-215 | Multisystem Endocrine Disorders | ESPE2019

Intestinal Ganglioneuromatosis as First Manifestation of Multiple Endocrine Neoplasia 2B in a Premature Girl

Leunbach Tina Lund , Madsen Mette , Nielsen Rasmus G , Hansen Dorthe , Mathiesen Jes S

Introduction: Multiple endocrine neoplasia 2B (MEN2B) is a rare cancer syndrome primarily caused by the M918T (95%) and A883F (<5%) germline mutations in the REarranged during Transfection (RET) proto-oncogene. Aggressive and early onset thyroid medullary carcinoma is the hallmark of the disease. Cure rates in M918T carriers who had thyroidectomy before and after 1 year of age were 83% and 15% respectively. More t...

hrp0092s9.1 | Heterogeneity of Paediatric Diabetes | ESPE2019

Diversity in Monogenic Diabetes Management and Prognosis

Njølstad Pål Rasmus

Monogenic forms of diabetes have specific treatments that differ from the standard care provided for type 1 and type 2 diabetes, making the appropriate diagnosis essential. Misclassification of all diabetes types may occur and healthcare providers should be aware of this possibility. A systematic approach to subjects who are newly diagnosed with diabetes can assist classification of common forms of diabetes and identify those in whom molecular investigation would be advantageo...

hrp0082p3-d2-826 | Growth (1) | ESPE2014

Usability and Safety of FlexPro® PenMate® in Patients, Caregivers and Healthcare Professionals (HCPs)

Wen Yanhong , Korsholm Conny Nohr , Klinck Rasmus , Kappelgaard Anne-Marie

Introduction: FlexPro® PenMate® (PenMate®) (Novo Nordisk A/S, Denmark) aims to reduce needle anxiety by hiding the needle during injection. This usability test validated the safe and effective use of PenMate® and the instructions for use (IFU) in patients with growth hormone (GH) deficiency (GHD), Turner syndrome (TS), Noonan syndrome (NS) and children born small for gestational age (SGA).Me...

hrp0095fc11.1 | Late Breaking | ESPE2022

Deep subcutaneous adipose tissue is associated with hyperinsulinemia in adolescents

Cerenius Sara Y. , Stenlid Rasmus , Aydin Banu , Weghuber Daniel , Bergsten Peter , Forslund Anders

Introduction: Abdominal subcutaneous adipose tissue (SAT) is subdivided into two depots by the fascia of Scarpa. The deep SAT (dSAT) and superficial SAT (sSAT) are morphologically and metabolically distinct, with dSAT reportedly being more similar to visceral adipose tissue (VAT) in terms of elevating the risk for obesity-related complications. Conversely, sSAT appears to be more similar to lower-body SAT. The relationship between dSAT and metabolic disease ha...

hrp0092p3-29 | Bone, Growth Plate and Mineral Metabolism | ESPE2019

Extreme Hypercalcaemia: Watch for Glycogen Storage Disease Type 1a with Hyperinsulinism

christesen henrik , Nielsen Rasmus G , Lund Allan M , Cananguez Arlen A , Schou Anders J

Background: Hypercalcaemia in infants may reach extreme levels due to hyperparathyroidism, subcutaneous fat necrosis, or vitamin D intoxication. Normal values for p-parathyroid hormone and p-calcitriol prompt search for other causes.Methods: Hospital file evaluation, case report.Results: A 5½-months-old Caucasian girl of non-consanguineous healthy parents was referred due to w...

hrp0082p2-d3-446 | Growth Hormone (2) | ESPE2014

Evaluation of the Safety and Usability of FlexPro® 30 mg/3 ml, for the Delivery of Norditropin® in Patients Requiring GH Therapy

Fuchs Gitte Schoning , Wen Yanhong , Klinck Rasmus , Qvist Marianne , Kappelgaard Anne-Marie

Introduction: This test assessed the safety and usability of FlexPro® 30 mg/3 ml (Novo Nordisk A/S, Denmark), a pen-injector for injection of human GH in patients with GH deficiency (GHD), Turner syndrome (TS), Noonan syndrome (NS) and children born small for gestational age (SGA), and validated the instructions for use (IFU) and instructional video.Methods: Children with GHD/SGA or TS/NS, adult patients, caregivers of patients with GHD/S...

hrp0098fc15.5 | Late Breaking | ESPE2024

Presence of neuropathy in children and adolescents with type 1 diabetes evaluated with bedside modalities

Agner Damm Julie , Dalgas-Madsen Amalie , Hansen Christian , Ascanius Pilgaard Kasper , Pociot Flemming , Willum Hansen Tine , Johannesen Jesper

Aims: To investigate the prevalence of diabetic polyneuropathy (DPN), cardiac autonomic neuropathy (CAN) and sudomotor dysfunction in children and adolescents with type 1 diabetes using bedside modalities. Secondly, to evaluate the co-existence of these types of diabetes neuropathies.Methods: Cross-sectional study including 221 children and adolescents with type 1 diabetes. DPN was assessed by vibration sensation thresho...

hrp0095fc11.6 | Late Breaking | ESPE2022

The follicle-stimulating hormone receptor is expressed in human pancreatic islet beta-cells and its activation increases glucose stimulated insulin secretion

Aydin Banu K. , Chowdhury Azazul , Incedal Ceren , Wen Quan , Cerenius Sara Y. , Stenlid Rasmus , Forslund Anders , Idevall Olof , Bergsten Peter

Background: Follicle-stimulating hormone (FSH) plays a key role in reproduction. The G-protein coupled FSH receptor (FSHR), is expressed primarily in gonads, and specifically binds FSH. FSHR is also expressed in vascular endothelium, osteoclasts, adipose tissue, monocytes and rodent pancreatic islets. Elevated FSH levels are associated with development of obesity, insulin resistance, osteoporosis, and cardiovascular disease. In a recent study, we showed that h...

hrp0095rfc11.1 | Late Breaking | ESPE2022

Six-months of treatment with exenatide improves glycemic control, but does not affect endogenous intact GLP-1 concentrations in adolescents with obesity

Stenlid Rasmus , Y. Cerenius Sara , K. Aydin Banu , S. Gjessing Erik , Manell Hannes , Weghuber Daniel , Forslund Anders , Bergsten Peter

Introduction: When used to treat obesity, glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RA) improve both BMI and metabolic health. Liraglutide is approved by both the EMA and FDA for the treatment of pediatric obesity, from 12 years and older. However, 26 weeks after discontinuation of liraglutide, the weight lost during treatment is regained. Prolonged exogenous stimulation of hormone-specific receptors may influence endogenous hormonal regulation. ...